NR3C2 and Duchenne muscular dystrophy: We have previously demonstrated that the mineralocorticoid receptor (MR) is present in skeletal muscle and represents a therapeutic target for treatment of skeletal muscle pathology in DMD (Rafael-Fortney et al., 2011; Chadwick et al., 2015; Lowe et al., 2016; Lowe et al., 2020).